 Telegraph.co.uk |
MedImmune parent, Amgen launch partnership
Gazette.Net: Maryland Community News Online AstraZeneca is to lead the development and commercial strategy of three candidates, AMG 139, AMG 157 and AMG 181, which are being studied to treat Crohn's disease, asthma and ulcerative colitis, respectively. Amgen will spearhead efforts regarding … Amgen and AstraZeneca Announce Collaboration to Jointly Develop and … Big Pharma Buys Access To This Promising Biotech Pipeline AstraZeneca, Amgen enter into development and commercialization agreement |
View full post on asthma – Google News